Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Active, not recruiting · Phase 2, Phase 3 · NCT02598661
Conditions: Myelodysplastic Syndromes
At a glance
- Research payments reported, 2025
- $427,866
- U.S. investigators named
- 9
- Sites paid
- 10
- Planned or actual enrollment
- 289
About the trial
- Sponsor
- Geron Corporation
- Tested
- Imetelstat Sodium (drug), Placebo (drug)
- Dates
- Started 2016-01-12; completion 2026-10-13
- Results posted
- Yes
The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 study and to compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat sodium to placebo in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment in Phase 3 study. A separate Ventricular Repolarization Substudy (QTc Substudy) will evaluate the effect of imetelstat sodium on ventricular repolarization. An Extension…
From ClinicalTrials.gov, last updated 2026-07-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Geron Corporation reported $427,866 in research payments for this study in 2025 (322 payments).
Products named: Imetelstat
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Antonio Di Stasi, M.D. Hematology & Oncology · Birmingham, AL
- Amer Zeidan Hematology & Oncology · New Haven, CT
- Rami S. Komrokji, M.D. Hematology · Tampa, FL
- Ralph V. Boccia, M.D. Hematology & Oncology · Bethesda, MD
- Azra Raza, M.D. Medical Oncology · New York, NY
- Uma M. Borate, MD Hematology · Columbus, OH
- Hetty Carraway, M.D. Hematology & Oncology · Chagrin Falls, OH
- Yazan Madanat, M.D Hematology & Oncology · Dallas, TX
- Bart L. Scott Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- H Lee Moffitt Cancer Center and Research Institute Hospital Inc $108,574
- Fred Hutchinson Cancer Research Center $101,687
- The University of Texas Southwestern Medical Center at Dallas $71,711
- Yale University $67,010
- Trustees of Columbia University $33,832
- The Ohio State University Office of Sponsored Programs $17,369
- Rcca MD LLC $11,086
- Cleveland Clinic, OH $10,872
- American Oncology PArtners P A $5,064
- University of Alabama Hospital, AL $660
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.